Skip to main
SCTX

SCTX Earnings Dates & Reports

SCTX Most Recent Earnings

Report Date
Period EndingQ3 2026
Est. EPS-$1.05
Actual EPS-$2.62
EarningsMiss

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

SCTX Earnings per Share (EPS) History

Signup for full access
Browse free

SCTX Latest Earnings

The value each SCTX share was expected to gain vs. the value each share gained.

SCTX reported its most recent earnings on for Q3 2026, posting earnings per share (EPS) of -$2.62. This exceeded analysts' expectations of -$1.05 by 149.52%, marking a Miss.

For comparison, Scribe Therapeutics Inc reported EPS of $0 in the same quarter last year.

The company is expected to announce its next earnings report on , with analysts projecting an EPS of -$0.93.

SCTX Earnings History

Earnings
Est. EPSActual EPSSurprise
Q4 2026
-$0.93
Q3 2026
-$1.05-$2.62+149.52%

SCTX Earnings Related Price Changes

Earnings announcements may impact a stock’s price. This table highlights the Scribe Therapeutics Inc’s price movement by comparing the day-before and day-after prices of recent earnings reports, along with the percentage change.

Report datePrice 1D beforePrice 1D afterChange

SCTX Earnings FAQs

SCTX last reported earnings on Sep 2, 2026 for Q3 2026, posting an EPS of -$2.62, which Miss the estimate of -$1.05 by 149.52%.

For Q3 2026, SCTX reported an EPS of -$2.62, missing analysts' estimate of -$1.05 by 149.52%.

For Q3 2026, SCTX Miss expectations with an actual EPS of -$2.62 vs. an estimated EPS of -$1.05.

Following the last earnings report on Sep 2, 2026, SCTX's stock price moved — from — to —.

The next SCTX earnings call is scheduled for Nov. 29, 2026, where executives will discuss financial results and outlook.

Scribe Therapeutics Inc (SCTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.